Commentary Open Access
Volume 1 | Issue 2 | DOI: https://doi.org/10.33696/pathology.1.010

Mechanistic and Translational Advances Using iPSC-Derived Blood Cells

  • 1Division of Neonatology, Children’s Hospital of Philadelphia, Philadelphia, PA, USA
  • 2Division of Hematology, Children’s Hospital of Philadelphia, Philadelphia, PA, USA
  • 3Center for Cellular and Molecular Therapeutics, Children’s Hospital of Philadelphia, Philadelphia, PA, USA
+ Affiliations - Affiliations

Corresponding Author

Christopher S Thom, thomc@chop.edu

Received Date: August 21, 2020

Accepted Date: October 21, 2020


Human induced pluripotent stem cell (iPSC)-based model systems can be used to produce blood cells for the study of both hematologic and non-hematologic disorders. This commentary discusses recent advances that have utilized iPSC-derived red blood cells, megakaryocytes, myeloid cells, and lymphoid cells to model hematopoietic disorders. In addition, we review recent studies that have defined how microglial cells differentiated from iPSC-derived monocytes impact neurodegenerative disease. Related translational insights highlight the utility of iPSC models for studying pathologic anemia, bleeding, thrombosis, autoimmunity, immunodeficiency, blood cancers, and neurodegenerative disease such as Alzheimer’s.


iPSC, Hematopoiesis, Developmental biology, Anemia, Thrombosis, Immunodeficiency, Cancer

Author Information X